This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Stocks to Buy to Be Like Buffett

DaVita

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Most of Berkshire Hathaway's buys in the second quarter were focused on stocks that the firm already had positions in, not new names. The biggest add-on buy came from DaVita (DVA - Get Report), a $9.2 billion company firm that runs more than 1,700 clinics and in-patient hospital dialysis units across the U.S., serving patients who suffer from chronic kidney failure.

Berkshire picked up 3.3 million shares of the firm last quarter, increasing its position by 50% and hiking its stake in the firm to 9.9% of outstanding shares.

>>5 Stocks With Big Insider Buying

DaVita's clinics serve patients who suffer from long-term kidney issues. That means that the firm's customers tend to be sticky: the better care DVA can provide, the healthier its 140,000 patients are, and the longer they'll be able to remain patients. As health problems like obesity continue to spread across the U.S. and tax Americans' kidneys, the number of diseases that require treatment from DaVita clinics should also continue to increase.

The firm is in the process of taking on a huge $4.4 billion merger that would change DVA's business from being dialysis-focused only into a more diversified healthcare facility portfolio. It's a move that makes sense for DVA, and Berkshire's investment managers know it. While healthcare reform will eventually knock Medicare payouts slightly, the larger pool of insured patients should lift DaVita's business overall - especially with a broader focus.

4 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
BK $43.47 0.00%
DVA $84.09 0.00%
NOV $50.71 0.00%
PSX $80.97 0.00%
WFC $56.00 0.00%

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs